Cite

HARVARD Citation

    Xu, J. et al. (2021). A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer. 127 (21), pp. 3975-3984. [Online]. 
  
Back to record